News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Citadel entities and Kenneth Griffin have filed an amended Schedule 13G/A, disclosing a beneficial ownership stake in FG Nexus Inc. (FGNX). Kenneth Griffin is reported to beneficially own 241,024 shares, representing 4.2% of the outstanding shares, while various Citadel Advisors entities hold 198,059 shares …
FG Nexus Inc. declared a quarterly cash dividend of $0.50 per share on its 8.00% Cumulative Preferred Stock, Series A, for the period June 15 to September 14, 2026. This marks the 34th consecutive quarter of distributions to preferred stockholders, with the dividend payable …
FG Nexus Inc. (Nasdaq: FGNX, FGNXP) announced a quarterly cash dividend of $0.50 per share on its 8.00% Cumulative Preferred Stock, Series A. The dividend is payable on September 15, 2026, to shareholders of record on September 1, 2026. This marks the 34th consecutive …
Damora Therapeutics Director Andrew Cheng was granted stock options to purchase 30,350 ordinary shares on August 12, 2026, as revealed in a recent SEC Form 4 filing. The options have an exercise price of $31 per share and will vest in equal monthly installments …
Damora Therapeutics director Andrew Cheng was granted 30,350 stock options on August 12, 2026, with an exercise price of $31.00 per share and an expiration date of August 12, 2036. These options will vest in equal monthly installments through August 12, 2029, contingent on …
Damora Therapeutics (DMRA) has filed a Form 3, an initial statement of beneficial ownership, for Andrew Cheng, identifying him as a new director. This filing officially establishes Cheng as a reporting person with the SEC, though it reports no stock transactions at this time. …
BEIJING and TEL AVIV, Israel, Aug. 13, 2026 /PRNewswire/ -- ADAMA Ltd. (SZSE: 000553), a leading global crop protection company, today announced the appointment of Orly Pascal as Chief Human Resources Officer (CHRO), and her joining ADAMA's Global Leadership Team, effective August 12th, 2026. …
Sharemaestro market context Price below Trend Line 52 weeks -21.4% · Next-week setup negative 44.8%RBC Capital has reiterated its Buy rating on Damora Therapeutics (DMRA.US), maintaining a target price of $40. This indicates a continued positive outlook from the firm regarding the company's stock performance.
FG Nexus Inc. (FGNX) reported its Q2 2026 results, showing a revenue increase to $242K from $207K year-over-year. Despite the revenue growth, the company posted a net loss of $(18.642M) and diluted EPS of $(3.07), a significant swing from a net income in the …
This article analyzes Newamsterdam Pharma Company N.v. (NAMS) through quantitative research, highlighting divergent sentiment and a test of support. It provides three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss points. The analysis also includes multi-timeframe signal strengths, …
NewAmsterdam Pharma (NAMS) reported a significant revenue drop and wider net loss in Q2 2026, with sales falling to US$3.7 million from US$19.15 million year-over-year and losses widening to US$64.14 million. This financial downturn, coupled with a 20% share price decrease, complicates the company's …
Damora Therapeutics, Inc. (DMRA) filed a post-effective amendment to its S-3 registration statement on August 10, 2026. This amendment follows the company's redomestication from Delaware to the Cayman Islands on July 16, 2026, and clarifies that no new securities are being registered. The filing …
Damora Therapeutics reported a net loss of $31.2 million for Q2 2026, a significant increase from $3.4 million in the prior year, primarily due to soaring R&D expenses for its CLARITY-101 trial. Despite the widening loss, the company boasts strong liquidity with $540.5 million …
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings, reporting a loss of $0.39 per share, which surpassed analysts' consensus estimate of a $0.45 loss by $0.06. Following the announcement, shares fell 1.3% to $29.54, resulting in a market capitalization of approximately $1.82 …
Damora Therapeutics, Inc. announced its financial results for the second quarter and first six months of 2026, ending June 30th. The company reported a significant increase in net loss for both periods compared to the previous year. For the second quarter, the net loss …
Damora Therapeutics, Inc. Common Stock (DMRA) reported Q2 2026 earnings on August 10, 2026, with an EPS of -$0.39, beating the consensus estimate of -$0.45. The company's earnings are projected to decrease in the next year, from ($2.06) to ($2.14) per share. The article …
Damora Therapeutics (DMRA) has initiated its Phase 1/1b CLARITY-101 trial for DMR-001, a first-in-class antibody targeting mutant calreticulin in myelofibrosis and essential thrombocythemia. This trial launch de-risks execution and provides a clear catalyst with mid-2027 data, though risks remain due to the company's early-stage, …
This page provides an overview of Damora Therapeutics, Inc. Common Stock (DMRA) including its current stock price, trends in media mentions, and page views. It also offers tools and resources for investors to monitor the stock, receive alerts, and conduct further research. The stock …
This article provides an earnings forecast for FG Nexus Ord Shs (FGNX), including analyst ratings and price targets. Based on 2 analysts, the stock has a "Buy" rating with an average target price of $12.00, representing a significant upside. The company's expected revenue for …
Search by ticker symbol or company name and select a result to open its chart.